Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025eJHaemOpen Access

Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHira MianJHJennifer S. HarperHLHoa H. Le

Discussion

Loading...

Member takes

Overview

Observational analysis reveals poor clinical outcomes in patients with triple-class exposed multiple myeloma, suggesting urgent need for new therapies.

Key Points

  • Poor clinical outcomes were observed in patients with triple-class exposed multiple myeloma receiving therapy.
  • The analysis identified 656 patients, with only 10.4% receiving the most common subsequent regimen, teclistamab.
  • Real-world data sourced from Komodo's Healthcare Map highlights the lack of a standard treatment of care in this population.
  • This finding underscores the need for novel treatments to improve outcomes among heavily pretreated patients.

Cite This Study

Mian et al. (2025) studied this question.

synapsesocial.com/papers/68d5d0d7ddad3c16d4635d35https://doi.org/10.1002/jha2.70145
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  2. 2Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing2025
  3. 3Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis2025
  4. 4Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study2025
  5. 5Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience2025